



Dkt. 48332-B/JPW/AJM/AG

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Carol M. Troy
Serial No.: 10/665,668
Filed : September 19, 2003
For : COMPOUNDS WHICH PREVENT CELL DEATH AND USES
THEREOF

1185 Avenue of the Americas
New York, New York 10036
January 20, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450
Mail Stop: Sequence

Sir:

**COMMUNICATION IN RESPONSE TO
NOVEMBER 19, 2003 NOTICE TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

This Communication is submitted in response to a November 19, 2003 Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures issued by the U.S. Patent and Trademark Office in connection with the above-identified application. A copy of the Notice is attached hereto as **Exhibit A**. A response to the November 19, 2003 Notice was due January 19, 2004. However, since January 19, 2004 falls on a federal holiday, a response filed on the next business day, i.e. Tuesday, January 20, 2004, shall be considered timely. Accordingly, this Communication is being timely filed.

The November 19, 2003 Notice states that the subject application fails to comply with the requirements of 37 C.F.R. §§1.821-1.825. Accordingly, the Notice requires applicant to

Applicant : Carol M. Troy
Serial No.: 10/665,668
Filed : September 19, 2003
Page 2


submit a Statement Pursuant to 37 C.F.R. §1.821(f) and a copy of the Sequence Listing in computer readable form.

In response to the Notice, applicant submits herewith a copy of the Sequence Listing on the enclosed computer diskette. In addition, applicant submits as **Exhibit B** a Statement In Accordance With 37 C.F.R. §1.821(f) certifying that the information in the computer readable form and that in the paper copy of the Sequence Listing are the same, and that the Sequence Listing does not introduce new matter.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorneys invite the Examiner to telephone them at the number provided below.


No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, NY 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450


Alan J. Morrison
Reg. No. 37,399

1/20/04
Date



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/665,668	09/19/2003	Carol M. Troy	48332-B JPW/AJM

John P. White
 Cooper & Dunham LLP
 1185 Avenue of the Americas
 New York, NY 10036



CONFIRMATION NO. 9076

FORMALITIES LETTER



OC000000011307834

Date Mailed: 11/19/2003

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
 Commissioner for Patents

P.O. Box 1450
Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE